Anthelmintic Drugs Market - Global Forecast 2026-2032

The Anthelmintic Drugs Market size was estimated at USD 3.86 billion in 2025 and expected to reach USD 4.17 billion in 2026, at a CAGR of 8.28% to reach USD 6.74 billion by 2032.

Anthelmintic drugs are essential antiparasitic medicines used to treat and control helminth infections across human health, animal health, and public health deworming programs. The category spans established deworming medicines such as albendazole, mebendazole, praziquantel, ivermectin, and pyrantel pamoate, with use cases covering soil-transmitted helminths, schistosomiasis, tapeworm infections, lymphatic filariasis-related programs, companion animal care, and livestock parasite control. The public health relevance remains substantial: WHO reports that soil-transmitted helminth infections affect an estimated 1.5 billion people, or about 24% of the global population, while more than 883 million children required preventive chemotherapy for soil-transmitted helminthiases in 2024. The industry’s strategic focus is therefore shifting from simple treatment availability toward assured quality, targeted administration, pediatric suitability, resistance monitoring, integrated diagnostics, and alignment with neglected tropical disease elimination goals. For SEO and stakeholder clarity, the anthelmintic drugs landscape is best understood through three intersecting priorities: expanding access to proven medicines in endemic communities, preserving drug efficacy through responsible use, and accelerating innovation for resistant or undertreated helminth infections.

The anthelmintic drugs landscape is undergoing transformative shifts as public health programs, veterinary care systems, and regulatory bodies move toward more evidence-driven parasite control. Preventive chemotherapy remains central to helminth control, with WHO recommending periodic albendazole or mebendazole for children in areas where baseline soil-transmitted helminth prevalence is 20% or higher, while praziquantel remains the recommended therapy for schistosomiasis control. At the same time, the field is responding to persistent treatment gaps: in 2024, global schistosomiasis treatment reached 39.6% of people requiring treatment and 61.7% of school-aged children requiring preventive chemotherapy, underscoring the need for better procurement, delivery, and age-appropriate formulations. Innovation is also becoming more practical and program-facing, as child-friendly praziquantel progressed through positive regulatory scientific opinion and WHO prequalification pathways to address preschool-aged children, a group historically underserved by large tablet formulations. In parallel, combination approaches are gaining attention, including ivermectin-albendazole scientific review for soil-transmitted helminth infections, reflecting a broader shift toward differentiated regimens, improved efficacy against difficult species, and more robust stewardship.

Artificial intelligence is beginning to influence the anthelmintic drugs ecosystem through faster compound prioritization, high-content phenotypic screening, diagnostic image analysis, transmission-risk modeling, and smarter allocation of deworming resources. In drug discovery, machine learning has already been applied to identify anti-schistosomal small molecules, while chemogenomic and high-content screening approaches are improving lead prioritization for parasitic worm diseases. AI also supports the search for new mechanisms of action, a critical need because current human and veterinary anthelmintic options rely on relatively few chemical classes and target pathways, while reduced efficacy and resistance pressures remain active concerns. The cumulative impact of AI is strongest when paired with curated parasite biology datasets, confirmatory wet-lab testing, field diagnostics, pharmacovigilance, and ethical governance. WHO’s 2024 AI-for-health work emphasizes science-based adoption, governance, ethical standards, regulation, risk mitigation, public health protection, and trust, which are especially important for AI tools used in neglected tropical disease programs and vulnerable populations. For industry leaders, AI should be viewed not as a replacement for parasitology expertise, but as an accelerator for target discovery, resistance surveillance, trial design, supply planning, and precision deworming strategies.

Asia-Pacific remains a priority region for anthelmintic drugs because soil-transmitted helminths are highly relevant across tropical and subtropical settings, while countries such as China and India demonstrate contrasting but instructive dynamics: China’s recent surveillance indicates low national soil-transmitted helminthiasis prevalence with geographic and demographic heterogeneity, while India maintains one of the world’s largest school- and community-based deworming platforms using albendazole for children and adolescents. North America is shaped less by mass preventive chemotherapy and more by prescription access, migrant and traveler health, pinworm and other household infections, companion animal deworming, and veterinary stewardship; in the United States, CDC lists oral albendazole, mebendazole, ivermectin, and pyrantel pamoate as available for human use, with indication-specific regulatory distinctions. Latin America combines endemic pockets, sanitation-linked transmission, and schistosomiasis control experience, with Brazil specifically recognized among countries where schistosomiasis control has been successfully implemented over decades. Europe is characterized by stringent medicine regulation, pharmacovigilance, travel medicine, imported infections, veterinary parasite control, and AI governance, including the EU’s harmonized AI framework that affects health-related digital tools. The Middle East shows a mixed profile of elimination achievements, imported infection management, and localized endemic histories, with WHO noting successful schistosomiasis control in Oman and Saudi Arabia. Africa is the most critical access region for praziquantel-based schistosomiasis programs and broad preventive chemotherapy, as WHO data indicate that Africa accounts for 94% of people requiring preventive chemotherapy for schistosomiasis and remains central to global deworming coverage goals.

ASEAN’s anthelmintic drugs priorities are anchored in tropical transmission settings, school-based deworming, schistosomiasis control in historically affected areas, sanitation integration, and cross-border disease surveillance, making reliable supply of albendazole, mebendazole, praziquantel, and ivermectin-linked program medicines strategically important. The GCC profile is different: strong health infrastructure, travel and migrant health screening, veterinary parasite management, and past schistosomiasis control achievements in Saudi Arabia and Oman shape a landscape focused on targeted treatment, surveillance, and importation risk rather than broad endemic burden. The European Union influences the global anthelmintic ecosystem through quality standards, regulatory scientific opinions, health data governance, pharmacovigilance, and AI oversight, including Regulation (EU) 2024/1689, which establishes a uniform framework for AI systems and aims to protect health, safety, and fundamental rights. BRICS countries collectively span high-burden and high-capability settings, with Brazil, China, India, and South Africa linking endemic disease control, domestic manufacturing capabilities, surveillance systems, and public health procurement needs. G7 countries play a disproportionate role in research funding, regulatory science, donor-backed neglected tropical disease programs, and quality assurance, while NATO members contribute mainly through medical logistics, deployment medicine, traveler health, and procurement standards rather than a disease-control mandate. Across all groups, the common strategic thread is the need to balance access expansion with efficacy preservation, especially as WHO continues to position preventive chemotherapy as a core intervention for soil-transmitted helminthiases and schistosomiasis.

The United States and Canada are primarily defined by regulated prescription access, imported parasitic infections, refugee and migrant health protocols, companion animal care, and veterinary stewardship, while Mexico and Brazil retain stronger links to endemic soil-transmitted helminths, sanitation-linked transmission, and targeted public health deworming. In Brazil, schistosomiasis remains a recognized public health concern and the country is also cited by WHO among nations with long-running schistosomiasis control experience. The United Kingdom, Germany, France, Italy, and Spain function as European access and regulation hubs where travel medicine, hospital parasitology, veterinary prescribing, pharmacovigilance, and compliance with EU-level digital health and AI rules shape anthelmintic drug use. Russia combines broad geography, veterinary parasite control, and targeted human parasitology needs, while China has shifted from historically high soil-transmitted helminth prevalence to low national prevalence with remaining local heterogeneity and ongoing transmission risk. India remains one of the most operationally significant countries for deworming medicines: its National Deworming Day approach uses single-dose albendazole for children and adolescents, and official 2024 reporting recorded 28.09 crore children covered in the February round. Japan, Australia, and South Korea are shaped by advanced regulatory systems, imported infection management, aquaculture and livestock parasite control, and precision veterinary use; Australia’s livestock systems are especially relevant to responsible anthelmintic use because global veterinary guidance identifies resistance management as essential to preserving drug effectiveness.

Industry leaders should prioritize quality-assured access to albendazole, mebendazole, praziquantel, ivermectin, and other clinically relevant deworming medicines while aligning production, distribution, and pharmacovigilance with WHO preventive chemotherapy strategies. Strategic investment should focus on pediatric-friendly formulations, heat-stable and field-suitable presentations, differentiated regimens for difficult-to-treat species, and evidence generation for combination therapy where supported by clinical data. Leaders should also strengthen anthelmintic resistance surveillance, especially across veterinary and One Health settings, because global animal-health guidance emphasizes responsible and prudent use to minimize resistance and reduce unnecessary drug exposure. Digital transformation should be implemented with clear governance: AI can support compound screening, epidemiological targeting, and supply planning, but models must be validated against field data, monitored for bias, and integrated with human parasitology expertise. Commercial and public health teams should collaborate with ministries, schools, laboratories, veterinary networks, and sanitation programs to ensure that deworming medicines are not deployed in isolation but embedded in diagnosis, hygiene education, safe water, sanitation, and reinfection prevention.

This executive summary is built on a secondary research methodology using verified public health, regulatory, and scientific sources, including WHO fact sheets and data platforms, CDC clinical guidance, peer-reviewed research, regulatory agency updates, and official public health documentation. The analysis excludes market sizing, market share, financial estimation, and forecasting, and instead focuses on disease burden indicators, preventive chemotherapy coverage, treatment recommendations, regulatory milestones, drug-efficacy considerations, resistance stewardship, regional access dynamics, and innovation pathways. Source triangulation emphasized current WHO datasets for soil-transmitted helminthiases and schistosomiasis, clinical treatment guidance for human anthelmintics, evidence on AI-enabled antiparasitic research, and One Health perspectives on responsible veterinary use. The methodology prioritizes data-backed interpretation over speculative claims, with special attention to terminology relevant for SEO visibility, including anthelmintic drugs, deworming medicines, soil-transmitted helminths, schistosomiasis treatment, praziquantel, albendazole, mebendazole, ivermectin, preventive chemotherapy, neglected tropical diseases, and anthelmintic resistance.

Anthelmintic drugs remain indispensable to global health, veterinary care, and neglected tropical disease control, but the next phase of progress depends on smarter access, stronger stewardship, and faster innovation. The evidence shows a clear dual reality: hundreds of millions of children still require preventive chemotherapy for soil-transmitted helminthiases, and more than 253 million people required preventive treatment for schistosomiasis in 2024, yet drug delivery gaps, pediatric formulation needs, and resistance concerns continue to challenge program effectiveness. The most resilient organizations will be those that combine reliable supply of proven medicines with improved formulations, AI-supported discovery, diagnostic integration, pharmacovigilance, and One Health resistance management. In an environment where public health goals, regulatory scrutiny, and treatment efficacy are increasingly connected, the anthelmintic drugs landscape is moving from volume-driven deworming toward precision, accountability, and sustainable parasite control.